Monitoring
Daily follow-up visits are recommended in severe cases in order to establish therapeutic efficacy and to monitor for adverse effects. If less severe, weekly visits are warranted. Corticosteroid medicines should be tapered slowly as improvement is seen. Regular intra-ocular pressure measurements should be recorded to assess for glaucoma. Once clinical improvement is witnessed, cycloplegic agents may be discontinued. The patient should be examined every 1 to 6 months for recurrence.
In the case of juvenile idiopathic arthritis (JIA)-associated uveitis, US guidelines recommend ophthalmological monitoring within 1 month after each change of topical corticosteroid, when tapering or discontinuing topical corticosteroids. For patients with JIA-associated uveitis on stable therapy, ophthalmological monitoring no less frequently than every 3 months is recommended. For patients with JIA-associated uveitis who are tapering or discontinuing systemic treatment, ophthalmological monitoring within 2 months of changing systemic treatment is recommended.[39]
Use of this content is subject to our disclaimer